Ohio State experts to review FDA regulation of prescription opioids


A team of Ohio State University experts has been awarded a contract through Brillient Corporation to complete an independent review of the Food and Drug Administration’s regulatory actions and decisions on currently approved opioid medications.

The review, due to be completed in January 2023, will also consider how to alter the agency’s approach to support appropriate use of opioid painkillers in an expanded public health context, said Patricia Zettler, associate professor in Ohio State’s Moritz College of Law, who is the subject matter lead for the team review.